Works by Ferron-Brady, Geraldine

Results: 16

Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 3, p. 203, doi. 10.1002/cpdd.139

By:

Koch, Kevin M.;
Ferron-Brady, Geraldine;
Lemmon, Colleen;
Cartee, Leanne;
Hollyfield, Hedy;
D'Amelio, Anthony M.;
Piepszak, Alexandra;
Swaby, Ramona F.;
Curran, David;
Arya, Niki

Publication type:

Article

Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.

Published in:

Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 5, p. 1282, doi. 10.1002/cpt.2409

By:

Ferron‐Brady, Geraldine;
Rathi, Chetan;
Collins, Jon;
Struemper, Herbert;
Opalinska, Joanna;
Visser, Sandra;
Jewell, Roxanne C.

Publication type:

Article

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.

Published in:

Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 1, p. 183, doi. 10.1007/s00280-014-2615-5

By:

Tolcher, Anthony;
Patnaik, Amita;
Papadopoulos, Kyriakos;
Rasco, Drew;
Becerra, Carlos;
Allred, Alicia;
Orford, Keith;
Aktan, Gursel;
Ferron-Brady, Geraldine;
Ibrahim, Nageatte;
Gauvin, Jennifer;
Motwani, Monica;
Cornfeld, Mark

Publication type:

Article

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.

Published in:

JNCI Cancer Spectrum, 2020, v. 4, n. 2, p. 1, doi. 10.1093/jncics/pkz093

By:

Piha-Paul, Sarina A;
Hann, Christine L;
French, Christopher A;
Cousin, Sophie;
Braña, Irene;
Cassier, Phillippe A;
Moreno, Victor;
Bono, Johann S de;
Harward, Sara Duckworth;
Ferron-Brady, Geraldine;
Barbash, Olena;
Wyce, Anastasia;
Wu, Yuehui;
Horner, Thierry;
Annan, Meg;
Parr, Nigel J;
Prinjha, Rabinder K;
Carpenter, Christopher L;
Hilton, John;
Hong, David S

Publication type:

Article

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor.

Published in:

Pharmacology Research & Perspectives, 2020, v. 8, n. 6, p. 1, doi. 10.1002/prp2.671

By:

Joshi, Samit R.;
Fernando, Disala;
Igwe, Stephanie;
McKenzie, Litza;
Krishnatry, Anu S.;
Halliday, Fiona;
Zhan, Joyce;
Greene, Thomas J.;
Jianfeng Xu;
Ferron-Brady, Geraldine;
Lataillade, Max;
Min, Sherene

Publication type:

Article

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Published in:

2022

By:

Roboz, Gail J.;
Yee, Karen;
Verma, Amit;
Borthakur, Gautam;
de la Fuente Burguera, Adolfo;
Sanz, Guillermo;
Mohammad, Helai P.;
Kruger, Ryan G.;
Karpinich, Natalie O.;
Ferron-Brady, Geraldine;
Acusta, Andre;
Del Buono, Heather;
Collingwood, Therese;
Ballas, Marc;
Dhar, Arindam;
Wei, Andrew H.

Publication type:

Letter

Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma.

Published in:

Clinical Pharmacokinetics, 2025, v. 64, n. 6, p. 925, doi. 10.1007/s40262-025-01508-1

By:

Papathanasiou, Theodoros;
Kaullen, Josh;
Polireddy, Kishore;
Chen, Xi;
Ho, Yu Liu;
Taylor, Adekemi;
Struemper, Herbert;
Carreño, Fernando;
Ferron-Brady, Geraldine

Publication type:

Article

Momelotinib: Mechanism of action, clinical, and translational science.

Published in:

CTS: Clinical & Translational Science, 2024, v. 17, n. 8, p. 1, doi. 10.1111/cts.70018

By:

Vlasakakis, Georgios;
McCabe, Michael T.;
Ho, Yu Liu;
Ferron‐Brady, Geraldine;
Martin, Paul;
Bentley, Darren;
Ellis, Catherine;
Antonysamy, Mary;
Visser, Sandra A. G.

Publication type:

Article

Clinical assessment of momelotinib drug–drug interactions via CYP3A metabolism and transporters.

Published in:

CTS: Clinical & Translational Science, 2024, v. 17, n. 4, p. 1, doi. 10.1111/cts.13799

By:

Ho, Yu Liu;
Gorycki, Pete;
Ferron‐Brady, Geraldine;
Martin, Paul;
Vlasakakis, Georgios

Publication type:

Article

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study.

Published in:

International Journal of Cancer, 2022, v. 150, n. 6, p. 993, doi. 10.1002/ijc.33861

By:

Cousin, Sophie;
Blay, Jean‐Yves;
Garcia, Irene Braña;
de Bono, Johann S.;
Le Tourneau, Christophe;
Moreno, Victor;
Trigo, Jose;
Hann, Christine L.;
Azad, Arun A.;
Im, Seock‐Ah;
Cassier, Philippe A.;
French, Christopher A.;
Italiano, Antoine;
Keedy, Vicki L.;
Plummer, Ruth;
Sablin, Marie‐Paule;
Hemming, Matthew L.;
Ferron‐Brady, Geraldine;
Wyce, Anastasia;
Khaled, Ahmed

Publication type:

Article

Building an adaptive dose simulation framework to aid dose and schedule selection.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 11, p. 1602, doi. 10.1002/psp4.13027

By:

Hooijmaijers, Richard;
Parasrampuria, Ridhi;
Marostica, Eleonora;
Ferron‐Brady, Geraldine;
Post, Teun M.;
Visser, Sandra A. G.

Publication type:

Article

Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 10, p. 1411, doi. 10.1002/psp4.13016

By:

Collins, Jon;
van Noort, Martijn;
Rathi, Chetan;
Post, Teun M.;
Struemper, Herbert;
Jewell, Roxanne C.;
Ferron‐Brady, Geraldine

Publication type:

Article

Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 5, p. 556, doi. 10.1002/psp4.12724

By:

Krishnatry, Anu Shilpa;
Hanze, Eva;
Bergsma, Tim;
Dhar, Arindam;
Prohn, Marita;
Ferron‐Brady, Geraldine

Publication type:

Article

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 8, p. 851, doi. 10.1002/psp4.12660

By:

Rathi, Chetan;
Collins, Jon;
Struemper, Herbert;
Opalinska, Joanna;
Jewell, Roxanne C.;
Ferron‐Brady, Geraldine

Publication type:

Article

Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 7, p. 709, doi. 10.1002/psp4.12639

By:

Krishnatry, Anu Shilpa;
Voelkner, Alexander;
Dhar, Arindam;
Prohn, Marita;
Ferron‐Brady, Geraldine

Publication type:

Article

An Adaptive Physiologically Based Pharmacokinetic–Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.

Published in:

Journal of Clinical Pharmacology, 2021, v. 61, n. 1, p. 125, doi. 10.1002/jcph.1711

By:

Riddell, Kylie;
Patel, Aarti;
Collins, Gary;
Zhou, Yanyan;
Schramek, Dan;
Kremer, Brandon E.;
Ferron‐Brady, Geraldine

Publication type:

Article